New Biologics for Atopic Diseases

To begin the course, please login or register by clicking ENROLL. After logging in, you will be able to complete the pretest and view the video/documents. You will have the option to complete the posttest, evaluation and receive credit. Some courses may have an associated cost.

Step Status
Video/Document(s)
Posttest
Evaluation
Starts On: 7/1/2018: 12:00 AM
Ends On: 6/30/2019: 12:00 AM
Session Type: Internet Activity Enduring Material
Credits: 0.75
Description:

Faculty


H. James Wedner, MD
Dr. Phillip and Arlene Korenblat Professor of Medicine
Chief, Division of Allergy and Immunology
Director, The Asthma and Allergy Center of Washington University
Disclosures
Company Name Relationship
CSL Behring Consulting/Advisory Committees
CSL Behring Consulting/Advisory Committees
Genetech Research Support/Grants
Genetech Speakers' Bureau/Honoraria
Shire Research Support/Grants
Shire Research Support/Grants
Merck & Company, Inc. Research Support/Grants

Presenters should indicate if speaking off label. This activity originated as a presentation at the CME activity, Clinical Allergy for the Practicing Physician, August 11-12, 2017, which was supported in part by Shire HGT, Inc., CSL Behring, and Lincoln Diagnostics, Inc.

Planning Committee


Tiffany Dy, MD
Assistant Professor, Medicine
Allergy and Immunology
Disclosures: No financial relationships to disclose.

Andrew L. Kau, MD, PhD
Instructor, Medicine
Division of Allergy/Immunology
Disclosures
Ownership Investment in Gilead Sciences, National Institutes of Health, and AAAAI Trust

Jennifer Monroy, MD
Assistant Professor, Medicine
Division of Allergy/Immunology
Disclosures: No financial relationships to disclose.

Sandra Odenwald, RN
Clinical Nurse Coordinator
Division of Allergy/Immunology
Disclosures: No financial relationships to disclose.
Objectives: The intended result of this activity is increased knowledge/competence, and upon completion of this course, participants should be able to:
  • Explain how biological products differ from conventional drugs
  • Describe the difference between precision medicine and personalized medicine
  • Describe treatments for atopic diseases
Additional Information:
Target Audience: This course is designed for allergists, immunologists, pulmonologists, primary care and family practice physicians, otolaryngologists, pediatricians, internists, dermatologists, nurse practitioners, physician assistants, nurses and all allied health professionals who care for patients with allergic and immunologic illnesses.

Date
Publication Date: July 1, 2018
Expiration Date: June 30, 2019

Accreditation Information:
wustlcme
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Awarded for this Activity:

Credit Statement: American Medical Association (AMA Credit)
Washington University School of Medicine in St. Louis designates this enduring material for a maximum of .75 AMA PRA Category 1 Creditâ„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

References:

  • Management of the patient with eosinophilic asthma: a new era begins

    Jantina C. de Groot, Anneke ten Brinke, Elisabeth H.D. Bel

    ERJ Open Research 2015 1: 00024-2015

  • The potential of biologics for the treatment of asthma

    Girolamo Pelaia, Alessandro Vatrella & Rosario Maselli

    Nature Reviews Drug Discovery 11, 958-972 (December 2012)

  • J Allergy Clin Immunol 2017;139:1311-21

  • N Engl J Med 2017; 376:2448-2458 June 22

Disclosure Information: It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations. Any potential conflicts were addressed and resolved.

Presenters are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients. All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests.

These presentations are the views and experiences of the presenters. The presenters' views do not represent the policy or position of Washington University School of Medicine in St. Louis. Washington University School of Medicine in St. Louis, Continuing Medical Education, is the provider for CME credits.



Powered By AI 4.5